Last reviewed · How we verify
NCT02346253
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
NA trial testing Internal Radiation Therapy in Prostate Adenocarcinoma in 146 participants. Participants enrolled and being followed up; not accepting new ones.
14 December 2021
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 146 |
| Start date | 13 January 2015 |
| Primary completion | 14 December 2021 |
| Estimated completion | 17 May 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Internal Radiation Therapy
- Bicalutamide (bicalutamide) — full drug profile →
- Leuprolide Acetate (leuprolide-acetate) — full drug profile →
- Goserelin Acetate (GOSERELIN ACETATE) — full drug profile →
- Triptorelin Pamoate
- Degarelix (degarelix) — full drug profile →
- Laboratory Biomarker Analysis
- Quality-of-Life Assessment
Conditions studied
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
- Stage I Prostate Cancer — all drugs for Stage I Prostate Cancer →
- Stage IIA Prostate Cancer — all drugs for Stage IIA Prostate Cancer →
- Stage IIB Prostate Cancer — all drugs for Stage IIB Prostate Cancer →
Sponsor
Stanford University
Who can join
Eligibility, male only, with Prostate Adenocarcinoma or Stage I Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor and may be a better treatment in patients with prostate cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The evolution of brachytherapy for prostate cancer.
Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, et al · · 2017 · cited 117× · PMID 28664931 · DOI 10.1038/nrurol.2017.76 -
Review of Current Treatment Intensification Strategies for Prostate Cancer Patients.
Wasim S, Park J, Nam S, Kim J. · · 2023 · cited 14× · PMID 38067321 · DOI 10.3390/cancers15235615 -
Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions.
Greenberger BA, Chen VE, Den RB. · · 2019 · cited 3× · PMID 31850194 · DOI 10.3389/fonc.2019.01273
Verify or expand the search:
- PubMed search for NCT02346253
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Internal Radiation Therapy
Trials testing the same drug.
- NCT04395079 — Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurre · Phase 2 · active not recruiting
- NCT03634267 — MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Can · Phase 1 · active not recruiting
- NCT01958580 — Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Remo · NA · terminated
- NCT01711515 — Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer · Phase 1 · completed
- NCT01295502 — Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical C · Phase 1 · unknown
Other recruiting trials for Prostate Adenocarcinoma
Currently open trials in the same condition.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
- NCT07025369 — Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With H · Phase 2 · recruiting
- NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02346253 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02346253.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing